Mitral annular calcification

Article written and reviewed by Dr Luca Moretti

Mitral annular calcification, or MAC, is a chronic fibrocalcific process involving the supporting structure of the mitral valve, most often in its posterior portion. On imaging it appears as a C-shaped hyperechoic or hyperdense structure, ranging from small focal deposits to a continuous mass surrounding much of the annulus. Calcification may remain incidental for years or invade the leaflet bases, alter opening and coaptation, and produce stenosis, regurgitation or a mixed lesion.

Mitral annular calcification is not simply a form of “wear and tear”, but the result of interactions among age, mechanical stress, inflammation, atherosclerosis, mineral metabolism and the susceptibility of fibrous tissue. Chronic kidney disease and hyperphosphatemia may accelerate its development, although many patients retain normal renal function. The finding also signals greater cardiovascular risk and overall biological vulnerability, but this does not justify automatically attributing every symptom or embolic event to MAC when valve dysfunction has not been demonstrated.

Its clinical relevance has increased with population aging and transcatheter procedures. A calcified annulus makes suturing, decalcification and surgical implantation hazardous; at the same time, it may provide irregular support for a valve-in-MAC prosthesis, exposing the patient to leak, embolization and outflow tract obstruction. Modern diagnosis must therefore define valve function, three-dimensional anatomy and procedural risk together.

Biology, risk factors and morphological variants

The process often originates in the region between the posterior annulus, leaflet base and ventricular myocardium. Oxidized lipids, inflammatory cells, apoptosis and matrix vesicles promote mineral nucleation, while interstitial cells may acquire an osteoblast-like phenotype; areas exposed to greater flexion and tension therefore concentrate damage. Calcification should consequently be understood as a biologically regulated process, even though no clinical therapy currently reverses it.

Advanced age is the most evident determinant. Hypertension, diabetes, dyslipidemia, smoking and atherosclerosis are frequently associated. In chronic kidney disease, abnormalities of phosphate, calcium, vitamin D, parathyroid hormone and fibroblast growth factor 23 promote extraskeletal calcification. Dialysis and longer duration of renal dysfunction increase the burden, but biochemical control does not guarantee regression of mature deposits.

Osteoporosis and MAC may coexist, expressing a vascular calcification-bone demineralization paradox mediated by age, inflammation and metabolism. Mediastinal radiotherapy produces fibrosis and calcium that often extend into the mitral-aortic continuity. Bicuspid aortic valve, calcific aortic stenosis and hypertrophic cardiomyopathy may modify loading of the apparatus, while rare metabolic syndromes can accelerate calcification.

The classic posterior distribution initially spares the commissures, distinguishing calcific stenosis from rheumatic heart disease. In advanced disease, calcium extends anteriorly and invades the trigones, posterior leaflet, myocardium and mitral-aortic continuity. Location, thickness, circumferential extent, extension into the leaflets and protrusion into the ventricle or atrium are described; a simple mild-severe dichotomy loses procedural information.

Caseous calcification of the annulus is a rare variant in which a calcific capsule encloses toothpaste-like material rich in calcium, lipids and debris. On echocardiography it forms a rounded hyperechoic mass with a relatively hypoechoic center and no internal flow; CT and magnetic resonance help distinguish it from tumor, abscess or vegetation. It may remain stable, transform, or rarely embolize.

MAC may involve the conduction system near the trigone and septum, and is associated with atrioventricular or bundle branch block. Its relationship to the circumflex artery and atrioventricular groove is crucial during surgery. Stiffness also alters saddle-shaped dynamics and annular contraction, increasing stress on the leaflets and modifying the point of coaptation.

Not every posterior echogenic density is calcium. Prostheses, surgical rings, groove fat, sutures and artifacts may produce similar echoes. CT distinguishes high-attenuation material and defines its margins; absence of calcium on CT requires reconsideration of a mass, thrombus or fibrous tissue. Comparison with an older image helps establish growth rate and nature.

Progression is not linear. Small deposits may remain stable, whereas kidney disease, inflammation and hemodynamic loading accelerate extension. Coronary calcium score and aortic calcium often increase in parallel, but MAC has its own biomechanics. No blood marker precisely predicts which annulus will become stenotic or unreconstructable.

Stenosis, regurgitation and clinical consequences

Calcific stenosis results from protrusion of calcium at the leaflet bases and reduced leaflet excursion. The orifice often assumes a tunnel-like or crescent shape, without the commissural fusion typical of rheumatic stenosis. The gradient depends on valve area, flow, heart rate and atrioventricular compliance; anemia, tachycardia and associated regurgitation may increase it without a proportional reduction in area.

MAC-related regurgitation results from several mechanisms: annular rigidity and reduced contraction, retraction of the posterior base, inadequate coaptation, calcium lifting a segment, nearby chordal rupture, or superimposed atrial dilation. Jet direction varies. The same valve may have both an elevated gradient and significant regurgitation, creating mixed dysfunction in which each component affects measurement of the other.

Dyspnea and reduced exercise tolerance are nonspecific in an older population with hypertension, atrial fibrillation, pulmonary disease, anemia and heart failure with preserved ejection fraction. To attribute them to MAC, a coherent hemodynamic abnormality must be demonstrated. A moderate resting gradient may increase with tachycardia and exercise; conversely, low flow may conceal important stenosis.

When calcification becomes hemodynamically significant, increased left atrial pressure promotes dilation, atrial fibrillation, congestion and pulmonary hypertension. The left ventricle, often small and stiff because of age, hypertrophy or amyloidosis, may make symptoms appear disproportionate to valve area alone; tricuspid regurgitation and right ventricular dysfunction may also develop in more advanced stages. For this reason, the mitral gradient must be interpreted within the entire cardiopulmonary circuit.

MAC is associated with atrial fibrillation, stroke, coronary artery disease, cardiovascular events and mortality. Part of this relationship reflects shared risk factors; other pathways include atrial enlargement, embolization of thrombus or calcific material, endocarditis and ulceration. The presence of MAC alone is not an independent indication for anticoagulation: rhythm, stenosis, thrombi and individual risk guide treatment.

Endocarditis may develop on irregular calcium and extend into the annulus. Vegetations may be difficult to distinguish from the hyperechoic background; blood cultures, transesophageal echocardiography, CT and, in selected cases, metabolic imaging contribute to diagnosis. Caseous calcification may mimic an abscess, but has a typical capsule and center and is not necessarily accompanied by systemic infection.

Prognosis depends on calcium burden, valve dysfunction and, above all, the overall clinical profile. Kidney disease, frailty, aortic disease, coronary artery disease and right ventricular dysfunction increase procedural risk and limit recovery. Extensive MAC without significant stenosis or regurgitation is a marker that must be contextualized; severe symptomatic dysfunction is a complex valve disease requiring assessment at an expert center.

Hemolysis may occur when a high-velocity jet passes through a calcific orifice or through a leak after prosthetic implantation. Anemia, elevated lactate dehydrogenase, reduced haptoglobin and schistocytes support the diagnosis, but bleeding and kidney disease are common alternatives. Correcting iron deficiency without addressing a major leak may temporarily improve hemoglobin without removing the mechanism.

Caseous calcification has been associated with cerebral embolism, especially when material communicates with a chamber or contains mobile components. Most asymptomatic cases are observed because surgery for a stable mass may be riskier than the natural history. Growth, recurrent emboli, severe dysfunction or persistent diagnostic uncertainty make individualized surgical discussion reasonable.

Echocardiography, CT and hemodynamic assessment

Transthoracic echocardiography is the first-line examination, but calcium produces bright echoes and acoustic shadowing that may obscure the leaflet bases and reduce Doppler quality. The report should therefore integrate the location and extent of calcification, leaflet mobility, mean gradient at the documented heart rate, regurgitation, chamber dimensions, pulmonary pressure and right ventricular function. Transesophageal echocardiography provides a better atrial perspective, although it too remains limited by posterior shadowing.

Two-dimensional planimetry is difficult because the orifice is nonplanar, irregular and located near the base. Pressure half-time is affected by atrial and ventricular compliance and is unreliable in degenerative stenosis. The continuity equation may fail with regurgitation, arrhythmia or inaccurate measurements. The mean gradient, although flow-dependent, remains an important parameter when interpreted with heart rate, stroke volume and symptoms.

Three-dimensional echocardiography allows multiplanar planimetry at the level of greatest restriction and visualizes the extent of disease when shadowing is not prohibitive. In regurgitation, vena contracta, PISA, pulmonary venous flow and volumetric methods are integrated. Multiple jets and crescent-shaped basal orifices make reliance on a single threshold inappropriate. Exercise can document increases in gradient and pulmonary pressure when symptoms and resting findings are discordant.

Cardiac CT is superior for defining calcium. Multiplanar reconstructions assess circumferential distribution, depth, extension into the trigones and leaflets, angles, annular dimensions and relationships with the circumflex artery and atrioventricular groove. Proposed quantitative scores are not yet universally standardized; reports should avoid transferring the coronary Agatston score to unvalidated mitral thresholds.

When planning transcatheter replacement, CT simulates prosthesis size and position, anchoring, sealing and the neo-outflow tract. The prosthesis displaces the anterior leaflet toward the septum, creating a neo-LVOT; a small predicted area, a prominent septum, a small ventricle, an unfavorable aorto-mitral angle and a long leaflet increase the risk of obstruction. The threshold is not absolute and depends on cardiac phase, device and preventive strategies.

Magnetic resonance quantifies volumes and regurgitation when echocardiography is inconclusive, but calcium appears as signal void and CT remains better for anatomy. Catheterization measures simultaneous atrial-ventricular gradients in discordant cases; pulmonary capillary wedge pressure does not always reproduce left atrial pressure and timing must be correct. Coronary assessment is part of the preoperative pathway.

Functional diagnosis requires distinguishing MAC-related dysfunction from concomitant disease. A patient may have a large calcium burden but ventricular secondary regurgitation, superimposed rheumatic stenosis or dyspnea from amyloidosis. Multimodality imaging should construct a unified explanation and state what remains uncertain, because intervention on the annulus will not resolve a dominant extracardiac cause.

In atrial fibrillation, multiple beats with similar cycle lengths are averaged; tachycardia and anemia should be corrected before stenosis is labeled on the basis of the gradient. In low-flow states, a modest gradient may coexist with a narrow orifice. Stroke volume, three-dimensional area, exercise response and, when necessary, invasive measurement help separate truly severe stenosis from moderate abnormality in a stiff ventricle.

Preprocedural CT should also assess left atrial appendage thrombus, interatrial septal anatomy, venous access, entry angle and calcification of the mitral-aortic continuity. Anchoring does not depend only on total calcium volume: a posterior bar without anterior support may promote tilting. Planning combines virtual simulation with anatomical judgment.

Medical therapy, surgery and transcatheter procedures

No drug can dissolve mitral annular calcification. Medical therapy acts on consequences and comorbidities by treating congestion, hypertension, ischemia, atrial fibrillation and vascular risk; in stenosis, rate control prolongs diastole and may reduce the gradient, whereas excessive preload reduction risks compromising output in a stiff patient. Mineral disorders of chronic kidney disease should be corrected according to nephrology recommendations, without promising regression of the valve lesion.

Intervention is considered when severe stenosis, regurgitation or mixed dysfunction causes symptoms or consequences not explained by other diseases and expected benefit exceeds risk. Complexity requires a Heart Valve Centre with dedicated imaging, surgery and interventional expertise. Operability is not equivalent to a numerical score: calcium distribution, the atrioventricular groove, coronary arteries, frailty and reconstructive options matter as much as risk scores.

Surgery may follow “resect” or “respect” strategies, each with a different balance between radical treatment and risk. Extensive decalcification allows annular reconstruction but exposes the patient to atrioventricular groove rupture, circumflex injury, hemorrhage and ventricular dysfunction; conservative techniques avoid part of the dissection by suturing the prosthesis to alternative tissue or covering the calcium, but increase the risk of leak, nonanatomical implantation or a small prosthesis. Patches and reconstruction therefore require specific expertise.

Repair is possible if regurgitation is the main problem and enough mobile tissue remains; calcium may prevent annuloplasty or secure suture purchase. Replacement is more common in calcific stenosis. A biological or mechanical prosthesis is chosen considering age, anticoagulation and reintervention, but anatomy may limit size and position.

TEER may reduce predominant regurgitation if the distal leaflet portions are mobile, not calcified in the grasping area, and valve area allows an acceptable residual gradient. It does not treat stenosis and may worsen it; subvalvular or commissural calcium and a wide gap reduce efficacy. Selection must include planimetry and gradient assessment before any clip procedure.

Valve-in-MAC uses a balloon-expandable valve, generally one originally designed for the aortic position, anchored within the native calcified annulus through transseptal, transapical or hybrid transatrial access. It is a high-risk procedure, often off-label or performed within selected programs, with mortality and complication rates higher than mitral valve-in-valve. Insufficient or poorly distributed calcium predisposes to migration; irregular calcium causes paravalvular leak and hemolysis.

Left ventricular outflow tract obstruction is the most feared complication and is associated with high mortality. Prevention may require anterior leaflet laceration with the LAMPOON technique, septal ablation, surgical leaflet resection, or a different device choice and implantation depth; none of these strategies, however, makes every anatomy treatable. CT simulation and a bailout plan are therefore mandatory parts of planning.

Dedicated transcatheter mitral replacement systems seek better anchoring and sealing, but access, profile, thrombosis, LVOT obstruction and durability remain challenges. Studies and approvals continue to evolve; a description current in 2026 should not be interpreted as universal availability. For patients unlikely to benefit despite technical success, medical treatment and symptom-focused care are active and appropriate choices.

The risk of atrioventricular groove rupture after surgery does not end in the operating room: contained hemorrhage, pseudoaneurysm or dehiscence may present postoperatively. Instability, effusion or anemia require urgent imaging. After ViMAC, paravalvular leak and hemolysis may require occluders, post-dilation or a repeat procedure, with every maneuver balanced against the risks of migration and LVOT obstruction.

Follow-up, complications and prognosis

Incidental MAC without significant dysfunction is followed according to extent, age and comorbidities. Serial echocardiography looks for an increasing gradient, new regurgitation, atrial dilation, pulmonary pressure and right ventricular function. There is no single interval: rapid progression, kidney disease, symptoms or concomitant aortic valve disease require closer follow-up.

The development of atrial fibrillation simultaneously changes symptoms and gradients and must be incorporated into clinical interpretation. Anticoagulation depends on thromboembolic risk and the valvular context, with specific assessment of the drug class when mitral stenosis is clinically significant; the likelihood of successful cardioversion and rhythm control depends on atrial size and arrhythmia duration. Rate control also requires balance, avoiding both tachycardia and excessive reduction in cardiac output.

An embolic event requires a search for atrial fibrillation, atrial thrombus, aortic atheroma, carotid disease, endocarditis and a mobile caseous lesion. Defining MAC as the source by exclusion alone may be reasonable in selected cases, but does not automatically justify surgery or permanent anticoagulation. The decision weighs recurrence, mass mobility and procedural risk.

After surgical or transcatheter treatment, prosthetic gradient, leak, LVOT, ventricular function, pulmonary pressure and conduction are documented. CT may assess prosthesis position and leaflet thrombosis; anticoagulant and antiplatelet treatment depend on the prosthesis, rhythm and bleeding risk. Hemolysis, a new murmur or heart failure require earlier reassessment.

An increase in gradient should be compared with heart rate and flow before thrombosis or degeneration is diagnosed. Leaflet thickening, reduced motion and CT attenuation help identify the mechanism. Empirical anticoagulation without assessing bleeding risk and anatomy may be dangerous in an older population; treatment requires a probable diagnosis and a reassessment plan.

Prognosis after treatment is strongly conditioned by patient selection. Patients with severe MAC are often excluded from standard procedures precisely because they are frail and have multiple comorbidities; direct comparison of outcomes among surgery, TMVR and medical therapy therefore creates substantial bias. Technical success with short survival and no functional recovery is not a good outcome; quality of life and days out of hospital must be part of the decision.

MAC ultimately represents a paradigm of structural cardiology: a common anatomical finding becomes disease only when it alters function, and a technically feasible solution becomes treatment only if it produces net benefit. Hemodynamic quantification, procedural CT, center experience and patient goals must converge before one of the most complex annuli to treat is approached.